GENEXCHAIN
1. Overview
The GeneXChain project aims to establish a blockchain-based decentralized platform that securely and reliably stores and manages highly valuable personal genetic information for each individual. Utilizing its proprietary DTC (Direct-To-Consumer) genetic analysis, the GeneXChain project offers personalized health solutions through AI technology. This system enables individuals to choose and manage the use of their genetic analysis data, rewarding them with tokens.
The core technology of the GeneXChain project, the DTC genetic testing system, bypasses medical institutions by providing consumers direct access to genetic testing services and results from testing agencies. This service is particularly advantageous as it provides tailored information on health, disease risks, and other trait characteristics to users using AI technology, and facilitates swift result delivery due to the simplicity of DNA sample collection.
Within the GeneXChain project, the GENX token, a BEP-20-based utility token, is used for covering the costs of genetic analysis tests, payments to affiliated medical institutions, community rewards, and donations. Additionally, HC (Health Credit) cash, an internal point system, is utilized for various services offered on the GeneXChain platform. Through the internally developed Wallet system, HC cash can be swapped with GENX tokens at a predetermined ratio.
The core technology of the GeneXChain project, the DTC genetic testing system, bypasses medical institutions by providing consumers direct access to genetic testing services and results from testing agencies. This service is particularly advantageous as it provides tailored information on health, disease risks, and other trait characteristics to users using AI technology, and facilitates swift result delivery due to the simplicity of DNA sample collection.
Within the GeneXChain project, the GENX token, a BEP-20-based utility token, is used for covering the costs of genetic analysis tests, payments to affiliated medical institutions, community rewards, and donations. Additionally, HC (Health Credit) cash, an internal point system, is utilized for various services offered on the GeneXChain platform. Through the internally developed Wallet system, HC cash can be swapped with GENX tokens at a predetermined ratio.
1.1 Health Management Status
Healthcare can be categorized into three distinct eras: Healthcare 1.0, Healthcare 2.0, and Healthcare 3.0.
The Healthcare 1.0 era spanned from the 18th century to the early 20th century, primarily focusing on the prevention of infectious diseases. During this period, significant efforts were dedicated to identifying the causes of these diseases and developing vaccines and treatments to combat them.
The Healthcare 2.0 era began with the onset of the 20th century. As the global economy and the medical industry advanced, nations established medical service systems aimed at disease treatment. The primary focus shifted from prevention to treatment during this time.
The Healthcare 3.0 era, which started in the 21st century, marks a transition from 'disease treatment' to 'disease prevention' and 'health management.' This era signifies a shift from reactive post-diagnosis medical care to predictive and preventative healthcare. Personalized, participatory medicine tailored to individual characteristics has become more prominent. Additionally, the transition to a contactless society has accelerated. Consequently, the healthcare industry is evolving from traditional hospital-centric care to consumer-centric, digital technology-based healthcare. This evolution underscores the increasing importance of active personal participation in the advancement of the healthcare industry.
'Data' has emerged as a pivotal element in the evolving healthcare paradigm that emphasizes disease prevention and health promotion. Integrating healthcare services with digital technology is crucial for collecting, storing, and analyzing this data. The convergence of healthcare services, digital technology, and ICT has given birth to a new industry known as 'digital health' or 'digital healthcare.' This industry aims to transform traditional in-hospital treatments into intelligent medical solutions accessible to people regardless of time and space constraints.
The defining feature of digital healthcare is the ability for individuals to receive health management services anytime and anywhere through various advanced information and communication technologies. Cutting-edge ICT technologies such as artificial intelligence, the Internet of Things, wearable devices, smartphones, and cloud computing are being rapidly and extensively integrated into healthcare systems. Governments worldwide, including those of the United States, Europe, Japan, China, and India, are planning and promoting measures to elevate the smart healthcare industry, which has emerged as the largest and fastest-growing market within the ICT convergence sector.
According to the market research firm Markets and Markets (MnM), the global digital health market is projected to grow from $169.7 billion in 2018 to $392 billion by 2024, with an annual growth rate of 15.5%. As the healthcare market expands, related services such as hospitals, beauty salons, fitness centers, and pharmacies also develop. However, many people find it inconvenient to utilize these services. For instance, consumers often face difficulties when choosing health services such as hospital visits. There is often a lack of necessary information to select suitable hospitals, making it challenging to find facilities specializing in specific conditions. Furthermore, the internet is flooded with inaccurate and unverified information and advertisements, hindering consumers from making rational choices. The overwhelming volume of data complicates the selection of appropriate products or services.
The Healthcare 2.0 era began with the onset of the 20th century. As the global economy and the medical industry advanced, nations established medical service systems aimed at disease treatment. The primary focus shifted from prevention to treatment during this time.
The Healthcare 3.0 era, which started in the 21st century, marks a transition from 'disease treatment' to 'disease prevention' and 'health management.' This era signifies a shift from reactive post-diagnosis medical care to predictive and preventative healthcare. Personalized, participatory medicine tailored to individual characteristics has become more prominent. Additionally, the transition to a contactless society has accelerated. Consequently, the healthcare industry is evolving from traditional hospital-centric care to consumer-centric, digital technology-based healthcare. This evolution underscores the increasing importance of active personal participation in the advancement of the healthcare industry.
'Data' has emerged as a pivotal element in the evolving healthcare paradigm that emphasizes disease prevention and health promotion. Integrating healthcare services with digital technology is crucial for collecting, storing, and analyzing this data. The convergence of healthcare services, digital technology, and ICT has given birth to a new industry known as 'digital health' or 'digital healthcare.' This industry aims to transform traditional in-hospital treatments into intelligent medical solutions accessible to people regardless of time and space constraints.
According to the market research firm Markets and Markets (MnM), the global digital health market is projected to grow from $169.7 billion in 2018 to $392 billion by 2024, with an annual growth rate of 15.5%. As the healthcare market expands, related services such as hospitals, beauty salons, fitness centers, and pharmacies also develop. However, many people find it inconvenient to utilize these services. For instance, consumers often face difficulties when choosing health services such as hospital visits. There is often a lack of necessary information to select suitable hospitals, making it challenging to find facilities specializing in specific conditions. Furthermore, the internet is flooded with inaccurate and unverified information and advertisements, hindering consumers from making rational choices. The overwhelming volume of data complicates the selection of appropriate products or services.
1.2 Issues with the Current Medical Information System
Anyone who has visited a hospital may have experienced a common situation: after receiving treatment at one hospital, a subsequent visit to a different hospital often involves repeating previously conducted tests or scans. The reason for this redundancy is that the information from the previous hospital does not get transmitted to the new one. This ineffective exchange of medical information stems from the fact that most current medical information systems are centered around individual medical institutions, coupled with government regulations due to the critical nature of medical information as highly sensitive personal data.
Under the current medical institution-centered management system, several issues arise: the reliability of medical data is not assured, transparency in data usage is low, and the risks of data loss or hacking are significant. Within such a system, individuals find it challenging to independently utilize their medical information, leading to inherently low data reliability and a constant concern for personal data privacy. Instances of medical data hacking, particularly in New York, are increasing annually. In 2015 alone, over 112 million medical records were hacked in the United States, with the resulting damages exceeding $6.2 billion annually
Medical institutions face several drawbacks due to the lack of medical information exchange: they cannot easily access a patient's past information, which hinders the ability to provide optimal care and necessitates unnecessary repeated tests, increasing both medical costs and patient burdens. There are also social issues stemming from instances where medical institutions falsely input or arbitrarily modify medical records. Unfortunately, the current medical information system lacks a systematic solution to effectively control these problems.
Under the current medical institution-centered management system, several issues arise: the reliability of medical data is not assured, transparency in data usage is low, and the risks of data loss or hacking are significant. Within such a system, individuals find it challenging to independently utilize their medical information, leading to inherently low data reliability and a constant concern for personal data privacy. Instances of medical data hacking, particularly in New York, are increasing annually. In 2015 alone, over 112 million medical records were hacked in the United States, with the resulting damages exceeding $6.2 billion annually
Medical institutions face several drawbacks due to the lack of medical information exchange: they cannot easily access a patient's past information, which hinders the ability to provide optimal care and necessitates unnecessary repeated tests, increasing both medical costs and patient burdens. There are also social issues stemming from instances where medical institutions falsely input or arbitrarily modify medical records. Unfortunately, the current medical information system lacks a systematic solution to effectively control these problems.
1.3 Birth of GeneXChain
In line with the Healthcare 3.0 era, GeneXChain aims to develop a platform that fosters contactless healthcare services, personalized medical services, and consumer participation, thereby establishing a cutting-edge digital healthcare system. This platform will facilitate the extensive use of medical information, applicable to a wide range of services from conventional hospital treatments to personalized mobile medical solutions.
By integrating blockchain, the foundational infrastructure of the Fourth Industrial Revolution, with its operations, GeneXChain enhances accessibility and reliability. This integration enables transparent management and oversight, creating a consumer-centric integrated medical information system that the existing system has failed to achieve. This means that anyone can freely exchange healthcare information, receive high-quality personalized healthcare services, and enjoy more convenient and secure healthcare benefits. The platform guarantees the extensive utilization of healthcare information, ranging from general hospital treatments to personalized mobile healthcare services.
Paradoxically, GeneXChain uses blockchain technology, which symbolizes decentralization, to achieve data integration. It can consolidate medical records created by healthcare institutions as well as patient-generated medical data. This system allows for the easy storage of data from various medical devices outside of healthcare institutions, as well as data created by individuals. The integrated medical information can be widely utilized for everything from general hospital treatments to personalized mobile healthcare services.
By integrating blockchain, the foundational infrastructure of the Fourth Industrial Revolution, with its operations, GeneXChain enhances accessibility and reliability. This integration enables transparent management and oversight, creating a consumer-centric integrated medical information system that the existing system has failed to achieve. This means that anyone can freely exchange healthcare information, receive high-quality personalized healthcare services, and enjoy more convenient and secure healthcare benefits. The platform guarantees the extensive utilization of healthcare information, ranging from general hospital treatments to personalized mobile healthcare services.
2. GeneXChain's Features
2.1 Purpose of GeneXChain
Most cryptocurrencies currently on the market address one or two aspects of the blockchain trilemma: decentralization, security, and scalability. Achieving all three simultaneously is often considered physically impossible.
GeneXChain aims to build a platform and ecosystem that securely and reliably stores and manages genetic testing data by leveraging blockchain technology. Genetic testing data is highly sensitive to individuals and statistically valuable, necessitating secure management and effective utilization. To address these issues, GeneXChain plans to integrate blockchain technology to develop a genetic testing data management platform. This platform is designed to benefit both individuals and institutions that utilize statistical data, creating a convenient and secure ecosystem.
GeneXChain aims to build a platform and ecosystem that securely and reliably stores and manages genetic testing data by leveraging blockchain technology. Genetic testing data is highly sensitive to individuals and statistically valuable, necessitating secure management and effective utilization. To address these issues, GeneXChain plans to integrate blockchain technology to develop a genetic testing data management platform. This platform is designed to benefit both individuals and institutions that utilize statistical data, creating a convenient and secure ecosystem.
2.1.1 Usage of GeneXChain (Genomic India Project)
GeneXChain aims to establish a blockchain-based open platform for securely collecting and managing all medical information, including diagnostic results of uninfected samples scattered across various institutions, as well as medical data produced through various devices such as mobile phones. The platform will support the GENEM INDIA policy initiative involving the Indian central government and 22 national and public institutions.
Medical consumers will have the right to own, manage, and control their medical information, with the option to record this data with consumer consent or obtain it for research purposes. The virtual asset GeneXChain, used on this platform, serves as a reward mechanism based on the contribution to information creation and provision. Not only consumers but also healthcare providers contributing to the production of medical information will be rewarded according to their contributions.
GeneXChain can be used as a payment method for various expenses, such as medical fees, prescription costs, and insurance premiums, within multiple institutions connected to GeneXChain. This initiative is based on the philosophy that blockchain can address the problems of the current medical information system.
Medical consumers will have the right to own, manage, and control their medical information, with the option to record this data with consumer consent or obtain it for research purposes. The virtual asset GeneXChain, used on this platform, serves as a reward mechanism based on the contribution to information creation and provision. Not only consumers but also healthcare providers contributing to the production of medical information will be rewarded according to their contributions.
GeneXChain can be used as a payment method for various expenses, such as medical fees, prescription costs, and insurance premiums, within multiple institutions connected to GeneXChain. This initiative is based on the philosophy that blockchain can address the problems of the current medical information system.
⇉ Non-technical, freely recorded text without excessive medical jargon
⇉ Memo pad document record UA/UI system applications
⇉ Resolution of issues such as slow speed and low-security technology
⇉ Addressing the problem of scattered and publicly disclosed medical records across various medical institutions
⇉ Solving the problem of limited medical information exchange between multiple medical institutions
⇉ Resolving the inconvenience of frequent issuance of various medical documents and re-consultations
⇉ Realizing the linkage of diagnostic results and medical-health data
⇉ Implementing remote-based personalized healthcare based on sample diagnostic results
For these reasons, the GeneXChain project group is preparing blockchain-based diagnostic services for intractable diseases and a simple insurance claim service as its main business in India.
⇉ Memo pad document record UA/UI system applications
⇉ Resolution of issues such as slow speed and low-security technology
⇉ Addressing the problem of scattered and publicly disclosed medical records across various medical institutions
⇉ Solving the problem of limited medical information exchange between multiple medical institutions
⇉ Resolving the inconvenience of frequent issuance of various medical documents and re-consultations
⇉ Realizing the linkage of diagnostic results and medical-health data
⇉ Implementing remote-based personalized healthcare based on sample diagnostic results
2.2 Scope of Blockchain Application
The GeneXChain ecosystem platform incorporates blockchain technology to perform the following functions:
1. Storage of Genetic Test Results: It securely stores the results obtained from genetic tests.
2. Data Provision Server: It acts as a server to provide data related to an individual’s genetic test results upon request. However, it does not store specific personal information on the blockchain. Instead, it generates a hash value that can be verified through personal information, ensuring connectivity through authorization checks.
3. Statistics on Genetic Test Results: It provides statistical analyses of the genetic test results.
2. Data Provision Server: It acts as a server to provide data related to an individual’s genetic test results upon request. However, it does not store specific personal information on the blockchain. Instead, it generates a hash value that can be verified through personal information, ensuring connectivity through authorization checks.
3. Statistics on Genetic Test Results: It provides statistical analyses of the genetic test results.
2.3 Personal Information Verification Process
To ensure the secure use of data included in the blockchain through the provided app, the personal information verification process is offered in the following sequence:
1. Storage of Personal Key and Hash Value: Store the tester's personal key and hash value related to the test records in the app.
2. Request to Store Public Key and Hash Value: Request the storage of the tester's public key and test record hash value on the blockchain.
3. Conversion and Storage of QR Code: Convert the tester's public key and test record hash value into a QR code and store it in the app.
Viewing and Sharing Test Results: Users can view, share, and utilize their test results within the app.
2. Request to Store Public Key and Hash Value: Request the storage of the tester's public key and test record hash value on the blockchain.
3. Conversion and Storage of QR Code: Convert the tester's public key and test record hash value into a QR code and store it in the app.
2.4 Data Utilization and Reward System
The GeneXChain ecosystem is structured as follows, utilizing genetic test result data:
Viewing Genetic Test Results:
Viewing Genetic Test Results:
· Users can view their genetic test results.
· Through the app, users can access analyzed data results stored on the blockchain in report form.
· Users securely request data on the blockchain using their personal key and test history hash value stored in the app.
Sharing Genetic Test Results:
· Through the app, users can access analyzed data results stored on the blockchain in report form.
· Users securely request data on the blockchain using their personal key and test history hash value stored in the app.
· Users can share their genetic test results with others.
· The individual tested can grant sharing permissions to specific recipients (e.g., their physician or family members) through the app.
· The recipient must use the app and provide their user ID to request access to the shared data.
· The sharing process utilizes blockchain-based transmission.
· The data sharing is executed by transferring the test record hash value from the tester’s wallet address to the recipient’s wallet address on the blockchain.
Consent for the Use of Genetic Test Results:
· The individual tested can grant sharing permissions to specific recipients (e.g., their physician or family members) through the app.
· The recipient must use the app and provide their user ID to request access to the shared data.
· The sharing process utilizes blockchain-based transmission.
· The data sharing is executed by transferring the test record hash value from the tester’s wallet address to the recipient’s wallet address on the blockchain.
· Users can consent to the use of their genetic test results.
· Upon consenting, users are rewarded with GeneXChain tokens for providing their information.
· No personally identifiable information is used; only limited information such as age, gender, and region is provided for statistical use.
Data Utilization by Institutions:
· Upon consenting, users are rewarded with GeneXChain tokens for providing their information.
· No personally identifiable information is used; only limited information such as age, gender, and region is provided for statistical use.
· Institutions can utilize statistical data from genetic test results.
· Institutions use GeneXChain tokens to access this information.
· The platform aims to provide well-categorized and highly accessible search functions and statistics.
· A blockchain specialized for statistical processing is employed to achieve this goal.
· Institutions use GeneXChain tokens to access this information.
· The platform aims to provide well-categorized and highly accessible search functions and statistics.
· A blockchain specialized for statistical processing is employed to achieve this goal.
3. Building the GeneXChain ecosystem
3.1. Genetic Testing
3.1.1 Genetic Testing Market
With the advent of the Healthcare 3.0 era, healthcare practices have significantly shifted from reactively treating diseases to focusing on preventive measures. This transition has heightened public interest in healthcare and disease prevention. Given the variability in disease risk among individuals, the need for personal genetic analysis to predict and proactively manage diseases has increased.
According to the (NBPRC) Biotech Policy Research Center’s report on the "Global Genetic Testing Market Status and Prospects," the genetic testing market is expected to grow at an annual rate of over 10%. The market, valued at $6.424 billion in 2018, is projected to nearly double to $11.798 billion by 2024.
In response to this rapid growth, plans are underway to introduce Direct-to-Consumer (DTC) genetic testing services. DTC genetic testing involves providing services directly to consumers without intermediaries, delivering results directly to them. These tests have the potential to enhance health awareness by providing personalized insights into health, disease risks, and other genetic traits. The ease of DNA sample collection and the rapid delivery of results are significant advantages.
Our analysis of individual genetic traits primarily focuses on single nucleotide polymorphisms (SNPs), which occur at a rate of one variation per 1,000 nucleotide sequences in the genome. These variations, represented by nucleotide bases A (adenine), T (thymine), C (cytosine), and G (guanine), contribute to genetic diversity and can predispose individuals to genetic diseases.
We can analyze mutations. People use their immunity to repair damaged DNA or eliminate cells with damaged DNA. However, if the DNA repair function and immunity decline due to lifestyle or aging, cells with mutated DNA may not be removed and can persist.
The genetic testing results are provided in two main categories: health and beauty. The health results reveal diseases that are likely to occur due to genetic factors, while the beauty results highlight genetic traits related to skin aging, hair loss, and other aesthetic aspects. Beyond identifying risk factors, we offer personalized care services, including lifestyle guides, nutritional analysis diets, and tailored cosmetic recommendations. Additionally, users can order, purchase, and customize products directly through the GeneXChain platform.
In response to this rapid growth, plans are underway to introduce Direct-to-Consumer (DTC) genetic testing services. DTC genetic testing involves providing services directly to consumers without intermediaries, delivering results directly to them. These tests have the potential to enhance health awareness by providing personalized insights into health, disease risks, and other genetic traits. The ease of DNA sample collection and the rapid delivery of results are significant advantages.
We can analyze mutations. People use their immunity to repair damaged DNA or eliminate cells with damaged DNA. However, if the DNA repair function and immunity decline due to lifestyle or aging, cells with mutated DNA may not be removed and can persist.
The genetic testing results are provided in two main categories: health and beauty. The health results reveal diseases that are likely to occur due to genetic factors, while the beauty results highlight genetic traits related to skin aging, hair loss, and other aesthetic aspects. Beyond identifying risk factors, we offer personalized care services, including lifestyle guides, nutritional analysis diets, and tailored cosmetic recommendations. Additionally, users can order, purchase, and customize products directly through the GeneXChain platform.
3.1.2 Brain Health and Mental Disorders Testing (Genetic Testing+Psychological Testing)
This program comprehensively diagnoses and treats disorders and symptoms related to neurodevelopment and neuropsychology. It targets brain and neurological disorders such as epilepsy, dementia, schizophrenia & autism spectrum, and attention deficit hyperactivity disorder (ADHD). By conducting both genetic and psychological tests concurrently, it assesses the causes (genetic vs. acquired) and quantitative/qualitative extents of symptoms. Additionally, it maximizes treatment effectiveness through tailored therapies based on the identified causes.
Currently, Western medicine and psychological approaches to mental health diagnosis are often separate. However, this diagnostic and treatment program allows for an integrated approach and diagnosis. Unlike physical health, accurate diagnosis and appropriate mental health treatment require both quantitative and qualitative testing. Furthermore, early intervention upon the onset of disorders is crucial due to significant differences in patient adaptation and rehabilitation depending on the timing of intervention.
The genetic testing results are integrated and provided in comprehensive reports categorized into health, beauty, cancer, and mental disorders. Health results indicate diseases that may occur due to genetic factors, while beauty results reveal genetic traits such as skin aging and hair loss. It provides probabilities of onset based on genetic factors, enabling comprehensive cancer health screening using genetic information.
For cancer and mental disorders: Health results indicate diseases that may occur due to genetic factors, while beauty results reveal genetic traits such as skin aging and hair loss. Cancer results provide probabilities of onset for various cancers using genetic information. Mental disorder testing identifies the occurrence of congenital diseases inherited from parents, such as epilepsy, dementia, schizophrenia & autism spectrum, and ADHD (attention deficit hyperactivity disorder). Additionally, it offers services such as personalized lifestyle guides, recommended diets considering nutrients, and personalized cosmetic recommendations. Users can also directly order and purchase customized products within the platform.
Currently, Western medicine and psychological approaches to mental health diagnosis are often separate. However, this diagnostic and treatment program allows for an integrated approach and diagnosis. Unlike physical health, accurate diagnosis and appropriate mental health treatment require both quantitative and qualitative testing. Furthermore, early intervention upon the onset of disorders is crucial due to significant differences in patient adaptation and rehabilitation depending on the timing of intervention.
The genetic testing results are integrated and provided in comprehensive reports categorized into health, beauty, cancer, and mental disorders. Health results indicate diseases that may occur due to genetic factors, while beauty results reveal genetic traits such as skin aging and hair loss. It provides probabilities of onset based on genetic factors, enabling comprehensive cancer health screening using genetic information.
3.2 Functional Medicine Testing**
3.2.1 Characteristics of Functional Medicine Testing
In conventional diagnostics, disease is often diagnosed based on whether symptoms exceed specified threshold ranges. However, functional medicine focuses on defining optimal ranges for health parameters, diagnosing mild diseases when these ranges are exceeded.
- Necessity for Functional Medicine Testing
Conventional health screenings typically address only simple symptoms, making it challenging to identify or treat underlying causes related to degenerative diseases, harmful environments, or lifestyle imbalances. Correcting lifestyle habits within a short treatment period is also difficult. Moreover, standard screenings lack specialized tests necessary to uncover the origins of diseases. Functional medicine testing integrates internal and external diagnostics with functional medicine to diagnose patients and identify many causes of modern chronic diseases. This testing uses non-invasive samples such as hair, saliva, and urine to analyze symptoms of unknown diseases, as well as to assess imbalances, metabolism, nutrition, detoxification, and immune function.
· Organic Acid Test: Provides a metabolic snapshot of the body by analyzing neurotransmitters, metabolic pathways, toxin accumulation, detoxification, and gut microbiota balance through energy metabolism and nutritional imbalance analysis. · Salivary Hormone Test: Measures adrenal hormones in saliva to analyze chronic stress and hormonal status. · Fatty Acid Metabolism Test: Analyzes the balance of fatty acids essential for cellular membranes, neurology, hormone production, and vitamin absorption. · Oxidative Stress Test: Evaluates the degree of oxidative stress by measuring the number of free radicals and antioxidant capacity, indicating imbalances caused by excessive production of oxidative substances or insufficient antioxidant defence. · Hair Heavy Metal and Mineral Test: Analyzes and measures the contamination level of toxic elements like mercury, lead, aluminium, arsenic, and cadmium, as well as the metabolism of essential minerals needed for bodily functions using hair samples. · Food Allergy Test: Measures IgG antibodies to identify foods that induce delayed hypersensitivity reactions, which gradually appear after consumption.
- Necessity for Functional Medicine Testing
Conventional health screenings typically address only simple symptoms, making it challenging to identify or treat underlying causes related to degenerative diseases, harmful environments, or lifestyle imbalances. Correcting lifestyle habits within a short treatment period is also difficult. Moreover, standard screenings lack specialized tests necessary to uncover the origins of diseases. Functional medicine testing integrates internal and external diagnostics with functional medicine to diagnose patients and identify many causes of modern chronic diseases. This testing uses non-invasive samples such as hair, saliva, and urine to analyze symptoms of unknown diseases, as well as to assess imbalances, metabolism, nutrition, detoxification, and immune function.
· Organic Acid Test: Provides a metabolic snapshot of the body by analyzing neurotransmitters, metabolic pathways, toxin accumulation, detoxification, and gut microbiota balance through energy metabolism and nutritional imbalance analysis. · Salivary Hormone Test: Measures adrenal hormones in saliva to analyze chronic stress and hormonal status. · Fatty Acid Metabolism Test: Analyzes the balance of fatty acids essential for cellular membranes, neurology, hormone production, and vitamin absorption. · Oxidative Stress Test: Evaluates the degree of oxidative stress by measuring the number of free radicals and antioxidant capacity, indicating imbalances caused by excessive production of oxidative substances or insufficient antioxidant defence. · Hair Heavy Metal and Mineral Test: Analyzes and measures the contamination level of toxic elements like mercury, lead, aluminium, arsenic, and cadmium, as well as the metabolism of essential minerals needed for bodily functions using hair samples. · Food Allergy Test: Measures IgG antibodies to identify foods that induce delayed hypersensitivity reactions, which gradually appear after consumption.
3.2.2 Microbiome
The microbiome refers to the collective combination of microbes and biological communities (ecosystems) that inhabit the human body, including their genetic information. The microbiome regulates immune function and produces various metabolic substances. Research has revealed associations between the microbiome and conditions such as obesity, diabetes, atopic dermatitis, as well as cancer, autoimmune diseases, and depression. Comprehensive genetic health screenings, including genetic and microbiome testing, can be conducted.
GeneXChain offers services that include microbiome testing. Using advanced genetic analysis technologies such as Next-Generation Sequencing (NGS) and Real-Time PCR, GeneXChain examines the entire gut microbiota to provide personalized dietary guidelines and assess disease risks.
GeneXChain has prepared a project to build a microbiome database and study changes in gut microbiota based on lifestyle habits.
Recent interest from various companies in the microbiome sector stems from revealing the market's potential through research and creating multiple business models. According to market research firm Frost & Sullivan, the global microbiome market is expected to grow to $108.7 billion by 2023.
A spokesperson from the Center (NBPRC) Biotech Policy Research Center stated, "As the association with diseases becomes evident, the microbiome has emerged as an innovative therapeutic technology," and further added, "Technologies will expand into various areas such as microbiome diagnostics, treatments, and pharmaceutical development."
The term microbiome more accurately refers to a broader 'microbial community' rather than specifically the gut microbiota. It's a familiar concept known to benefit our bodies, termed 'probiotics.' Probiotics are well-known health supplements in various forms such as pills or powders that introduce beneficial bacteria into our intestines to support their well-being. Furthermore, research is underway on skincare products containing probiotics and prebiotics.
Many pharmaceutical companies are actively developing microbiome-based therapies. Recent basic science research has shown associations between the microbiome and chronic diseases, metabolic disorders, cardiovascular diseases, and cancer. Research is ongoing to develop microbiome-related pharmaceuticals for therapeutic use, although no approved medications currently exist, with some pipelines progressing through Phase 3 studies. We plan to continue research on microbiome-related health management in line with these trends.
GeneXChain offers services that include microbiome testing. Using advanced genetic analysis technologies such as Next-Generation Sequencing (NGS) and Real-Time PCR, GeneXChain examines the entire gut microbiota to provide personalized dietary guidelines and assess disease risks.
GeneXChain has prepared a project to build a microbiome database and study changes in gut microbiota based on lifestyle habits.
Recent interest from various companies in the microbiome sector stems from revealing the market's potential through research and creating multiple business models. According to market research firm Frost & Sullivan, the global microbiome market is expected to grow to $108.7 billion by 2023.
A spokesperson from the Center (NBPRC) Biotech Policy Research Center stated, "As the association with diseases becomes evident, the microbiome has emerged as an innovative therapeutic technology," and further added, "Technologies will expand into various areas such as microbiome diagnostics, treatments, and pharmaceutical development."
The term microbiome more accurately refers to a broader 'microbial community' rather than specifically the gut microbiota. It's a familiar concept known to benefit our bodies, termed 'probiotics.' Probiotics are well-known health supplements in various forms such as pills or powders that introduce beneficial bacteria into our intestines to support their well-being. Furthermore, research is underway on skincare products containing probiotics and prebiotics.
Many pharmaceutical companies are actively developing microbiome-based therapies. Recent basic science research has shown associations between the microbiome and chronic diseases, metabolic disorders, cardiovascular diseases, and cancer. Research is ongoing to develop microbiome-related pharmaceuticals for therapeutic use, although no approved medications currently exist, with some pipelines progressing through Phase 3 studies. We plan to continue research on microbiome-related health management in line with these trends.
3.3 Information Sharing Platform
As interest in the healthcare sector continues to rise, there is a growing demand among consumers for trustworthy information. Currently, people share extensive information about hospitals, clinics, medical services, and cosmetic treatments on existing platforms. However, the abundance of unverified information poses a challenge for consumers seeking accurate and reliable details. Misleading advertisements that exaggerate the benefits of specific products or services further complicate the search for genuine information.
GeneXChain's Approach
GeneXChain aims to address these issues by establishing an information-sharing community within its platform. This initiative allows consumers to exchange more accurate and trustworthy information. Through mechanisms such as voting and active participation in discussions, the platform will enhance the credibility of shared information. We incentivize trustworthy information providers to promote the dissemination of reliable content.
Our goal is to create a comprehensive healthcare ecosystem that encompasses medical services, cosmetic treatments, fitness programs, and psychological counseling. GeneXChain seeks to empower individuals with a deeper understanding of healthcare options and services by actively involving them in sharing and accessing information networks.
Advantages of AI-Based Personalized Genomics Services
1. Personalized Health Management:
Personalized services based on genomic information accurately reflect individual characteristics. This optimization enables enhanced effectiveness in disease prevention, treatment planning, and nutrition management, maximizing the efficacy of healthcare.
2. Accurate Diagnosis and Treatment:
Utilizing genetic data allows for a more precise understanding of disease causes, thereby increasing the accuracy of diagnoses and treatments. Tailored treatment plans considering each patient's genetic profile maximize therapeutic efficacy.
3. Efficient Drug Development:
Leveraging genetic information in drug development aids in creating medications that are effective for patients with specific genetic mutations. This approach enhances the success rate of drug development, reduces side effects, and accelerates the market release of effective therapies.
4. Promotion of Healthy Lifestyles:
Recommending healthy lifestyle habits based on individual genetic information facilitates personalized health management. For instance, personalized diets can be recommended based on genetic variations that indicate specific nutrient needs.
5. Disease Prevention:
Predicting the likelihood of genetic diseases through genetic analysis allows for preventive measures. Early detection through such predictions significantly aids in preventing health issues.
6. Innovative Advancements in Healthcare:
These personalized services drive innovative advancements in the medical field, enhancing individual health and quality of life.
These advantages illustrate how AI-based personalized genomics services play a crucial role in improving healthcare outcomes and empowering individuals with tailored health management solutions.
GeneXChain's Approach
GeneXChain aims to address these issues by establishing an information-sharing community within its platform. This initiative allows consumers to exchange more accurate and trustworthy information. Through mechanisms such as voting and active participation in discussions, the platform will enhance the credibility of shared information. We incentivize trustworthy information providers to promote the dissemination of reliable content.
Our goal is to create a comprehensive healthcare ecosystem that encompasses medical services, cosmetic treatments, fitness programs, and psychological counseling. GeneXChain seeks to empower individuals with a deeper understanding of healthcare options and services by actively involving them in sharing and accessing information networks.
Advantages of AI-Based Personalized Genomics Services
1. Personalized Health Management:
Personalized services based on genomic information accurately reflect individual characteristics. This optimization enables enhanced effectiveness in disease prevention, treatment planning, and nutrition management, maximizing the efficacy of healthcare.
2. Accurate Diagnosis and Treatment:
Utilizing genetic data allows for a more precise understanding of disease causes, thereby increasing the accuracy of diagnoses and treatments. Tailored treatment plans considering each patient's genetic profile maximize therapeutic efficacy.
3. Efficient Drug Development:
Leveraging genetic information in drug development aids in creating medications that are effective for patients with specific genetic mutations. This approach enhances the success rate of drug development, reduces side effects, and accelerates the market release of effective therapies.
4. Promotion of Healthy Lifestyles:
Recommending healthy lifestyle habits based on individual genetic information facilitates personalized health management. For instance, personalized diets can be recommended based on genetic variations that indicate specific nutrient needs.
5. Disease Prevention:
Predicting the likelihood of genetic diseases through genetic analysis allows for preventive measures. Early detection through such predictions significantly aids in preventing health issues.
6. Innovative Advancements in Healthcare:
These personalized services drive innovative advancements in the medical field, enhancing individual health and quality of life.
These advantages illustrate how AI-based personalized genomics services play a crucial role in improving healthcare outcomes and empowering individuals with tailored health management solutions.
4. Applications
4.1 Genetic Analysis
GeneXChain plans to enable consumers to afford genetic analysis testing costs. By integrating GeneXChain technology into the GeneXChain website and application, consumers can easily deposit GeneXChain purchased from external exchanges and conveniently pay for genetic analysis testing fees. Personal genetic information is sensitive health data, and leveraging blockchain security technology ensures safer storage and management of genetic information. Additionally, recommendations for cosmetics, health supplements, and other products will be provided based on the test results. Services will include tailored dietary and behavioral guidelines aligned with customers' genetic health.
4.2 Community Use within Local Communities
Through the GeneXChain application, plans include creating a community where individuals interested in genetic analysis results and healthcare can share information. Contributors of information within the community will receive evaluations of the value of the information they provide, rewarded through GeneXChain. Users participating in evaluations and contributing opinions to GeneXChain also receive compensation.
4.3 Donation to International Rare Diseases Association
GeneXChain is committed to actively participating in the International Rare Diseases Association's mission to support patients suffering from rare diseases, enabling them to have better quality of life and hope. Established as a non-profit social organization, the International Rare Diseases Association began its "Support Program for Medical Expenses for Rare Disease Patients" in 2001. This initiative aims to alleviate the high medical costs burden faced by individuals with chronic kidney disease, muscular dystrophy, hemophilia, Gaucher's disease, and other rare diseases.
4.4 Collaboration with Medical Institutions
GeneXChain facilitates collaboration with healthcare institutions to provide specialized information on medical fields and diseases. Physicians and experts in specific fields participate in the community to answer questions, directly connecting consumers with healthcare professionals. Consumers can receive specialized and detailed answers, while physicians can promote hospitals for marketing purposes.
Additionally, GeneXChain partners with shopping malls to streamline consumer access to recommended products within the platform. This partnership enhances convenience from product recommendations to purchases, aiming to integrate mobile payments through GeneXChain when matching patients with hospitals.
Additionally, GeneXChain partners with shopping malls to streamline consumer access to recommended products within the platform. This partnership enhances convenience from product recommendations to purchases, aiming to integrate mobile payments through GeneXChain when matching patients with hospitals.
5. GeneXChain Platform Overview
GeneXChain aims to address the challenge of reliable information exchange in healthcare through the establishment of an information-sharing community within its platform. Mechanisms such as voting and active participation in discussions are employed to enhance the credibility of shared information. Incentives are provided to trustworthy information providers to promote the dissemination of reliable content.
Our goal is to create a comprehensive healthcare ecosystem that encompasses medical services, beauty treatments, fitness programs, and psychological counseling. GeneXChain seeks to empower individuals with a deeper understanding of medical options and services by actively engaging them in sharing and accessing information through our network.
Provider and Consumer Interaction on GeneXChain Platform On the GeneXChain platform, genetic information providers can utilize the Provider dApp to commission their genome sequencing analysis and receive the results securely stored in the platform's decentralized distributed storage, encrypted for privacy. Consumers can use GENX tokens to request access to specific genomic information via the Consumer dApp. Upon consumer requests, GeneXChain lists anonymized genomic information from providers that match the specific genomic data requirements.
Providers who possess genomic information relevant to consumer requests can use the Provider dApp to confirm channels through which they can voluntarily grant access to their genomic information. Consumers gain access rights to specific individual genomic information repositories via the Consumer dApp and simultaneously compensate providers with GENX tokens for access. This process ensures secure management and exchange of genetic data, fostering a transparent and mutually beneficial interaction between genetic information providers and consumers within the GeneXChain ecosystem.
GeneXChain Platform System Overview
As depicted in the diagram above, the GeneXChain platform integrates a decentralized information storage system with the Binance blockchain network. The process involving the decentralized Inter Planetary File System (IPFS) within the platform operates as follows:
Encryption and Storage of Genetic Testing Results:
Genetic test results generated on the GeneXChain platform are encrypted and subsequently stored on IPFS.
Role of IPFS Clients:
IPFS clients (including individuals, pharmaceutical companies, health/beauty care enterprises, and research institutions) utilize the DATA cache DB associated with each client to search for desired content (such as DNA result reports) using IPNS (Inter Planetary Name Service).
Downloading DNA Result Documents:
To receive results, clients pay a specified amount of GENX tokens via a smart contract to the DNA Management dApp. Subsequently, they can download DNA result documents from IPFS.
Through this process, the GeneXChain platform introduces significant differentiation from traditional cloud infrastructure designs. By implementing a truly decentralized information storage and management system, it goes beyond merely decentralizing transaction histories and token transfers via smart contracts, extending to decentralizing content itself, thus embodying a genuine blockchain platform.
Provider and Consumer Interaction on GeneXChain Platform On the GeneXChain platform, genetic information providers can utilize the Provider dApp to commission their genome sequencing analysis and receive the results securely stored in the platform's decentralized distributed storage, encrypted for privacy. Consumers can use GENX tokens to request access to specific genomic information via the Consumer dApp. Upon consumer requests, GeneXChain lists anonymized genomic information from providers that match the specific genomic data requirements.
Providers who possess genomic information relevant to consumer requests can use the Provider dApp to confirm channels through which they can voluntarily grant access to their genomic information. Consumers gain access rights to specific individual genomic information repositories via the Consumer dApp and simultaneously compensate providers with GENX tokens for access. This process ensures secure management and exchange of genetic data, fostering a transparent and mutually beneficial interaction between genetic information providers and consumers within the GeneXChain ecosystem.
GeneXChain Platform System OverviewEncryption and Storage of Genetic Testing Results:
Genetic test results generated on the GeneXChain platform are encrypted and subsequently stored on IPFS.
Role of IPFS Clients:
IPFS clients (including individuals, pharmaceutical companies, health/beauty care enterprises, and research institutions) utilize the DATA cache DB associated with each client to search for desired content (such as DNA result reports) using IPNS (Inter Planetary Name Service).
Downloading DNA Result Documents:
To receive results, clients pay a specified amount of GENX tokens via a smart contract to the DNA Management dApp. Subsequently, they can download DNA result documents from IPFS.
Through this process, the GeneXChain platform introduces significant differentiation from traditional cloud infrastructure designs. By implementing a truly decentralized information storage and management system, it goes beyond merely decentralizing transaction histories and token transfers via smart contracts, extending to decentralizing content itself, thus embodying a genuine blockchain platform.
6. Tokenomics
The GeneXChain platform ecosystem forms a token economy mediated by GENX tokens and the Health Credit (HC) points system. GENX and HC are utilized within the platform as means of value exchange, payment methods for purchasing goods, and rewards.
GENX Token:
Utility: Based on the BEP20 standard, GENX serves as a means to pay for genetic analysis tests, costs associated with affiliated medical institutions, community rewards, and donations. It can be purchased on various global exchanges, stored, and transferred using a proprietary wallet service. GENX holdings can be converted into cash through withdrawal or exchanged for other virtual assets via the Binance Smart Chain network's wallet service.
Use Cases:
Providers of genetic databases receive GENX as compensation for their contributions. GENX holds monetary value within the GeneXChain platform, enabling purchases from the GeneXChain team and affiliated companies or utilization of services provided by partner companies.
Community Engagement:
- Genetic database providers engage in economic activities within the GeneXChain Platform dApp. They participate in a community where they share medical knowledge and stay informed about trends in the medical industry, including treatments and therapies for various diseases.
Health Credit (HC):
Primary Payment Method: HC serves as the primary payment and settlement method for consumer activities within the platform, organically connecting the platform's ecosystem.
Acquisition: Users can earn HC through platform operational policies, and HC obtained through rewards can be exchanged for GENX according to internally defined exchange rates.
This token economy design ensures fluid transactions and incentivizes active participation within the GeneXChain platform, fostering a dynamic ecosystem for utilizing medical and genetic data.
Utility: Based on the BEP20 standard, GENX serves as a means to pay for genetic analysis tests, costs associated with affiliated medical institutions, community rewards, and donations. It can be purchased on various global exchanges, stored, and transferred using a proprietary wallet service. GENX holdings can be converted into cash through withdrawal or exchanged for other virtual assets via the Binance Smart Chain network's wallet service.
Use Cases:
Providers of genetic databases receive GENX as compensation for their contributions. GENX holds monetary value within the GeneXChain platform, enabling purchases from the GeneXChain team and affiliated companies or utilization of services provided by partner companies.
Community Engagement:
- Genetic database providers engage in economic activities within the GeneXChain Platform dApp. They participate in a community where they share medical knowledge and stay informed about trends in the medical industry, including treatments and therapies for various diseases.
Health Credit (HC):
Primary Payment Method: HC serves as the primary payment and settlement method for consumer activities within the platform, organically connecting the platform's ecosystem.
Acquisition: Users can earn HC through platform operational policies, and HC obtained through rewards can be exchanged for GENX according to internally defined exchange rates.
This token economy design ensures fluid transactions and incentivizes active participation within the GeneXChain platform, fostering a dynamic ecosystem for utilizing medical and genetic data.
7. Token Plan
GENX Token Matrix
Token name: GENEXCHAIN
Ticker: GENX
Standard: BEP20
Total Supply: 7,000,000,000 GENX
Token Distribution
Ecosystem 30%: It is used to reward users for their contribution to major blockchain services that can be linked to the GeneXChain project’s dApp.
Token Sale 20%: This is the token sale volume for securing seeds and manpower required for the initial business and development costs.
Marketing & Operation 20%: This portion will be reserved for future ecosystem development, including social media marketing, and community events and operation.
Team & Advisors 15%: Compensate the core team who developed the platform and its infrastructures and strategic advisors to the protocol.
Partnership 5%: Will be conditionally distributed based on the achievement of a particular milestone.
Reserve 10%%: Tokens reserved for future growth capital rounds, community grants, network growth, partnerships, liquidity provisioning, etc. Vesting is to be decided at the time of distribution and based on the nature of usage and it will unlock after the announcement on the Foundation’s official GitHub and Medium.
Token name: GENEXCHAIN
Ticker: GENX
Standard: BEP20
Total Supply: 7,000,000,000 GENX
Ecosystem 30%: It is used to reward users for their contribution to major blockchain services that can be linked to the GeneXChain project’s dApp.
Token Sale 20%: This is the token sale volume for securing seeds and manpower required for the initial business and development costs.
Marketing & Operation 20%: This portion will be reserved for future ecosystem development, including social media marketing, and community events and operation.
Team & Advisors 15%: Compensate the core team who developed the platform and its infrastructures and strategic advisors to the protocol.
Partnership 5%: Will be conditionally distributed based on the achievement of a particular milestone.
Reserve 10%%: Tokens reserved for future growth capital rounds, community grants, network growth, partnerships, liquidity provisioning, etc. Vesting is to be decided at the time of distribution and based on the nature of usage and it will unlock after the announcement on the Foundation’s official GitHub and Medium.
8. GeneXChain ROAD MAP
2024 3Q
Project R&D, Marketing prep, Advisor consultation, Legal, Token Pre-sale
Additional Partnership in India, System check with Private data
2024 4Q
Marketing campaign, Gene System check development, Gene R&D
De-centralized application with simple data I/O for DNA and healthcare information on top of blockchain.
Project Mobile app development starts
2025 1Q~2Q
Project Mobile App launching
GeneXChain rewards schemes, DNA-SQ Get schemes launching
Expansion global PR & Marketing of the GeneXChain platform
Additional Partnership with global institutions
Project R&D, Marketing prep, Advisor consultation, Legal, Token Pre-sale
Additional Partnership in India, System check with Private data
2024 4Q
Marketing campaign, Gene System check development, Gene R&D
De-centralized application with simple data I/O for DNA and healthcare information on top of blockchain.
Project Mobile app development starts
2025 1Q~2Q
Project Mobile App launching
GeneXChain rewards schemes, DNA-SQ Get schemes launching
Expansion global PR & Marketing of the GeneXChain platform
Additional Partnership with global institutions
9. Team Members
DEVLINA CHAKRAVARTY
• Current) Director of ARTEMIS Hospital Chain
• A hospital chain famous for its best reputation and reliability in India)
• Apollo Tire Group> affiliated organization
• (Current) Prime Minister Modi’s Medical Advisory Group
• (Current) Member company of INDIA BUSINESS FORUM
• Area of expertise) Radiation therapy, hospital administration COO : Mr. Paramjit Singh
• Managing Director of Meta Ocean Ventures Private Limited
• Over three decades of experience in beverage industry
• Established Famous Grouse as a leading scotch in Indian market.
• Post reorganization of Global Business of Edrington in India, he has successfully introduced new brands in the Indian market for local companies
• Over 30 years of experience of introducing new brands in the Indian market for local companies
• Worked with both International companies and domestic companies, Paramjit has been associated directly with the trade.
• Companies associated - Pepsi, UB Group, Shaw Wallace, Whyte Mackey Group Scotland (India), Remy Martin Group France (India), Edrington Group Scotland (India).
• His expertise is in creation of consumer centric brands and marketing them through the complex landscape of the Indian Market.
• Over 32 years of professional experience Marketing medical device (Testing and medical equipment) in India
• Senior advisor of GeneXChain project Dr. MOHD. ZAID ANSARI
• Ph.D. in Chemistry, from Jamia Islamia Millia, Central University, (NAAC A++), New Delhi, India. (2019).
• Research Scholar at Dept. of Applied Sciences & Humanities, Faculty of Engineering and Technology, Jamia Millia Islamia, New Delhi.
• Bachelor’s in education (B.Ed) from Dr. Bheem Rao Ambedkar University, (NAAC A++), Agra India (2011-12).
• M.Sc. (Chemistry), Aligarh Muslim University, Aligarh, India (2009).
• Former Researcher at Aligarh Muslim University, Aligarh, India
• Project Title: “Mesoporous photocatalyst for the degradation of organic pollutant”
• Former Guest lecturer at Mahila P.G. College, Uttar Pradesh.
• Specialization: Inorganic, physical, and organic chemistry
• Former Guest lecturer: University polytechnic, Jamia Millia Islamia University
• Subject Taught: Electronic material & Component.
• Organizing member of international conference occurred in the Dept. Of Applied Mathematics F/O Engineering &Technology Jamia Millia Islamia-New Delhi Mr. Abdul Wasiq Waqif
• Master of Public Policy (Development Economics) Lee Kuan Yew School of Public Policy, National university of Singapore (2020-2022)
• Bachelor of business Management (financial management), Andhra University, India (2011-2014).
• Awarded Lee foundation graduate scholarship, LKY School of Public Policy, National university of Singapore (2020).
• Awarded ICCR Undergraduate Scholarship, Andhra University, India (2011).
• Brand ambassador at Ginger Promotions Ltd, United Kingdoms (2022-present)
• Refugee support volunteer, British Red Cross, UK (current)
• Former Social media monitor, Thomson Reuters, Singapore.
• Former Business Development Advisor, Women in Economy, USAID, Afghanistan.
• Former Executive officer, Ministry of Higher Education, Afghanistan. Dr. Mohd Shoaib Khan
• Assistant Professor (Research Faculty) at KL University, Andhra Pradesh, India.
• Research interests: Topological Data Analysis, Machine Learning, and Computer Vision.
• Ph.D. in Applied Mathematics from the South Asian University in New Delhi, India.
• Masters in Pure Mathematics from Aligarh Muslim University in Aligarh, India.
• Awarded a research grant (CSIR-JRF) by the Council of Scientific and Industrial Research, Government of India, with an All-India Rank of 66.
• Granted recognition by the European Society for Fuzzy Logic and Technology in Spain.
• Chaired the Volunteered Committee in the "International conference on Mathematical Analysis and Its Applications" held at the South Asian University.
• Member of the Algebraic Topology Research Network.
• Member of IEEE, IEEE Computational Intelligence Society.
• Member of the European Society for Fuzzy Logic and Technology.
• Reviewer of several reputed journals and conferences.
• Reviewer for Qeios, an open platform for empowering researchers. CEO : AHMAD SARFARAZ
• Chief Executive Officer of GeneXChain
• Former administrative assistant at KDI School of Public Policy and Management
• Former project coordinator at Development Knowledge Open Access Project (DKOA), KDI School of Public Policy and Management
• Extensive experience in blockchain technology, including leading multiple blockchain projects and initiatives CTO : Afzal Khaleel
• Chief Technology Officer of GeneXChain
• Former Microsoft India senior system analyst
• Former equity research analyst in Infosys in India
• Performed a quantitative and qualitative detailed review of fund financial statements, ensuring technical accuracy, completeness. Accounting policies & quality standards are maintained and improved as appropriate.
• Strong understanding of the current requirements of the accounting standards (IFRS, Irish GAAP and/or US GAAP) for various fund products
• Analyze data to identify emerging opportunities and risks.
• Identify actionable investment ideas. Help the team to create alpha by providing timely buy/sell recommendations.
• Maintain proper documentation and constant coverage of industry-related news, trends, and developments. Disseminate your insight to the team on a timely basis.
CMO : Ms. Anita Sahay
• Human Resources Manager at The Grand New Delhi (Grand Hyatt), Delhi, India
• Expert in recruiting manpower, onboard and train them
• Former Manager in Gostops Hospitality Pvt. Ltd., New Delhi, India
• Former Assistant Manager in Elite Biotech, New Delhi, India
• Former Assistant Manager in Indian Political Action Committee, Kolkata, India
• Former HR Analyst in Bada Business (Initiative by Vivek Bindra), New Delhi, India
• Former HR Executive in RKFL, Jamshedpur, India
• Master’s in Business Administration from Birla Institute of Technology, Ranchi, India
• Former HR Assistant in Tata Hitachi Construction Machinery, Jamshedpur, India Dr. Somnath Acharya
• Ph.D. in School of Basic Sciences, Indian Institute of Technology (IIT) Mandi, India
• Over 10 years of research experience in Experimental Condensed Matter Physics, Material Science, Thermoelectric Materials, Thermal & Electrical Transport
• Published in more than 15 highly reputed peer-reviewed international journals and attended several International and national conferences
• Reviewed several highly reputed international journals such as ACS applied energy materials; Nanotechnology; Journal of Physics D: Applied Physics
• Former Post-Doctoral Fellow, Department of Metallurgical Engineering and Materials Science, Indian Institute of Technology Bombay, India
• Former junior research fellow, Indian Institute of Science Bengaluru, India
• Former guest lecturer (Physics), Sammilani Mahavidyalaya (Affiliated to Calcutta University), Kolkata, India
• Master of Science (Physics), West Bengal State University, India
• Teaching assistantships at IIT Mandi
• Qualified Graduate Aptitude Test in Engineering (GATE) 2012 (Physics)
• International travel grant from Science and Engineering Research Board (SERB)
• A hospital chain famous for its best reputation and reliability in India)
• Apollo Tire Group> affiliated organization
• (Current) Prime Minister Modi’s Medical Advisory Group
• (Current) Member company of INDIA BUSINESS FORUM
• Area of expertise) Radiation therapy, hospital administration COO : Mr. Paramjit Singh
• Over three decades of experience in beverage industry
• Established Famous Grouse as a leading scotch in Indian market.
• Post reorganization of Global Business of Edrington in India, he has successfully introduced new brands in the Indian market for local companies
• Over 30 years of experience of introducing new brands in the Indian market for local companies
• Worked with both International companies and domestic companies, Paramjit has been associated directly with the trade.
• Companies associated - Pepsi, UB Group, Shaw Wallace, Whyte Mackey Group Scotland (India), Remy Martin Group France (India), Edrington Group Scotland (India).
• His expertise is in creation of consumer centric brands and marketing them through the complex landscape of the Indian Market.
• Over 32 years of professional experience Marketing medical device (Testing and medical equipment) in India
• Senior advisor of GeneXChain project Dr. MOHD. ZAID ANSARI
• Research Scholar at Dept. of Applied Sciences & Humanities, Faculty of Engineering and Technology, Jamia Millia Islamia, New Delhi.
• Bachelor’s in education (B.Ed) from Dr. Bheem Rao Ambedkar University, (NAAC A++), Agra India (2011-12).
• M.Sc. (Chemistry), Aligarh Muslim University, Aligarh, India (2009).
• Former Researcher at Aligarh Muslim University, Aligarh, India
• Project Title: “Mesoporous photocatalyst for the degradation of organic pollutant”
• Former Guest lecturer at Mahila P.G. College, Uttar Pradesh.
• Specialization: Inorganic, physical, and organic chemistry
• Former Guest lecturer: University polytechnic, Jamia Millia Islamia University
• Subject Taught: Electronic material & Component.
• Organizing member of international conference occurred in the Dept. Of Applied Mathematics F/O Engineering &Technology Jamia Millia Islamia-New Delhi Mr. Abdul Wasiq Waqif
• Bachelor of business Management (financial management), Andhra University, India (2011-2014).
• Awarded Lee foundation graduate scholarship, LKY School of Public Policy, National university of Singapore (2020).
• Awarded ICCR Undergraduate Scholarship, Andhra University, India (2011).
• Brand ambassador at Ginger Promotions Ltd, United Kingdoms (2022-present)
• Refugee support volunteer, British Red Cross, UK (current)
• Former Social media monitor, Thomson Reuters, Singapore.
• Former Business Development Advisor, Women in Economy, USAID, Afghanistan.
• Former Executive officer, Ministry of Higher Education, Afghanistan. Dr. Mohd Shoaib Khan
• Research interests: Topological Data Analysis, Machine Learning, and Computer Vision.
• Ph.D. in Applied Mathematics from the South Asian University in New Delhi, India.
• Masters in Pure Mathematics from Aligarh Muslim University in Aligarh, India.
• Awarded a research grant (CSIR-JRF) by the Council of Scientific and Industrial Research, Government of India, with an All-India Rank of 66.
• Granted recognition by the European Society for Fuzzy Logic and Technology in Spain.
• Chaired the Volunteered Committee in the "International conference on Mathematical Analysis and Its Applications" held at the South Asian University.
• Member of the Algebraic Topology Research Network.
• Member of IEEE, IEEE Computational Intelligence Society.
• Member of the European Society for Fuzzy Logic and Technology.
• Reviewer of several reputed journals and conferences.
• Reviewer for Qeios, an open platform for empowering researchers. CEO : AHMAD SARFARAZ
• Former administrative assistant at KDI School of Public Policy and Management
• Former project coordinator at Development Knowledge Open Access Project (DKOA), KDI School of Public Policy and Management
• Extensive experience in blockchain technology, including leading multiple blockchain projects and initiatives CTO : Afzal Khaleel
• Former Microsoft India senior system analyst
• Former equity research analyst in Infosys in India
• Performed a quantitative and qualitative detailed review of fund financial statements, ensuring technical accuracy, completeness. Accounting policies & quality standards are maintained and improved as appropriate.
• Strong understanding of the current requirements of the accounting standards (IFRS, Irish GAAP and/or US GAAP) for various fund products
• Analyze data to identify emerging opportunities and risks.
• Identify actionable investment ideas. Help the team to create alpha by providing timely buy/sell recommendations.
• Maintain proper documentation and constant coverage of industry-related news, trends, and developments. Disseminate your insight to the team on a timely basis.
CMO : Ms. Anita Sahay
• Expert in recruiting manpower, onboard and train them
• Former Manager in Gostops Hospitality Pvt. Ltd., New Delhi, India
• Former Assistant Manager in Elite Biotech, New Delhi, India
• Former Assistant Manager in Indian Political Action Committee, Kolkata, India
• Former HR Analyst in Bada Business (Initiative by Vivek Bindra), New Delhi, India
• Former HR Executive in RKFL, Jamshedpur, India
• Master’s in Business Administration from Birla Institute of Technology, Ranchi, India
• Former HR Assistant in Tata Hitachi Construction Machinery, Jamshedpur, India Dr. Somnath Acharya
• Over 10 years of research experience in Experimental Condensed Matter Physics, Material Science, Thermoelectric Materials, Thermal & Electrical Transport
• Published in more than 15 highly reputed peer-reviewed international journals and attended several International and national conferences
• Reviewed several highly reputed international journals such as ACS applied energy materials; Nanotechnology; Journal of Physics D: Applied Physics
• Former Post-Doctoral Fellow, Department of Metallurgical Engineering and Materials Science, Indian Institute of Technology Bombay, India
• Former junior research fellow, Indian Institute of Science Bengaluru, India
• Former guest lecturer (Physics), Sammilani Mahavidyalaya (Affiliated to Calcutta University), Kolkata, India
• Master of Science (Physics), West Bengal State University, India
• Teaching assistantships at IIT Mandi
• Qualified Graduate Aptitude Test in Engineering (GATE) 2012 (Physics)
• International travel grant from Science and Engineering Research Board (SERB)
10. Legal Notice, Disclaimer, and Limitation of Liability
This document is intended solely for informational purposes and does not constitute investment advice or an offer to invest. It is provided for the understanding of investors, and any other use is strictly prohibited.
As this document is not a contract or agreement, it may be subject to changes at the discretion of the company (including its representatives, affiliates, individuals, advisors, institutions, etc.) without prior notice. The company is not obligated to notify or disclose modifications, changes, or amendments to this document.
Efforts are made to provide the latest and accurate information about GENX in this document; however, information may be freely and actively modified due to technological progress and developments without prior notice. The company does not guarantee the suitability, accuracy, or completeness of the information provided. Additionally, the absence of specific information does not imply any liability on our part.
This document includes forward-looking statements such as "expect," "intend," "plan," "will," "goal," "purpose," and "may," as well as a roadmap outlining future plans. These forward-looking statements involve known and unknown risks and uncertainties, and actual events or results may significantly differ from those included in the forward-looking statements in this document.
While the company commits to faithfully execute the contents of this document for the advancement of GENX, such commitment does not guarantee inherent value, stable pricing, or profitability of GENX. Furthermore, GENX does not constitute a part of our equity, nor does it confer such rights and authorities.
The information provided in this document has not been reviewed or approved by any regulatory authority; therefore, the distribution of this document does not imply compliance with relevant legal and regulatory requirements.
Cryptocurrencies are not legal tender. They are subject to significant price volatility and can be profoundly affected by market conditions, governmental regulations, technological limitations, and other factors.
Regulatory actions or investigations related to cryptocurrency businesses and operations may impact our business and delay or disrupt future business developments. Therefore, cryptocurrency investors should make investment decisions based on their own judgment and bear responsibility for investment losses. Investors are advised to consult with experts on technical, legal, financial, tax, or other responsibilities before making investment decisions.
The company disclaims any responsibility for direct or indirect losses incurred by investors relying on the information provided in this document.
As this document is not a contract or agreement, it may be subject to changes at the discretion of the company (including its representatives, affiliates, individuals, advisors, institutions, etc.) without prior notice. The company is not obligated to notify or disclose modifications, changes, or amendments to this document.
Efforts are made to provide the latest and accurate information about GENX in this document; however, information may be freely and actively modified due to technological progress and developments without prior notice. The company does not guarantee the suitability, accuracy, or completeness of the information provided. Additionally, the absence of specific information does not imply any liability on our part.
This document includes forward-looking statements such as "expect," "intend," "plan," "will," "goal," "purpose," and "may," as well as a roadmap outlining future plans. These forward-looking statements involve known and unknown risks and uncertainties, and actual events or results may significantly differ from those included in the forward-looking statements in this document.
While the company commits to faithfully execute the contents of this document for the advancement of GENX, such commitment does not guarantee inherent value, stable pricing, or profitability of GENX. Furthermore, GENX does not constitute a part of our equity, nor does it confer such rights and authorities.
The information provided in this document has not been reviewed or approved by any regulatory authority; therefore, the distribution of this document does not imply compliance with relevant legal and regulatory requirements.
Cryptocurrencies are not legal tender. They are subject to significant price volatility and can be profoundly affected by market conditions, governmental regulations, technological limitations, and other factors.
Regulatory actions or investigations related to cryptocurrency businesses and operations may impact our business and delay or disrupt future business developments. Therefore, cryptocurrency investors should make investment decisions based on their own judgment and bear responsibility for investment losses. Investors are advised to consult with experts on technical, legal, financial, tax, or other responsibilities before making investment decisions.
The company disclaims any responsibility for direct or indirect losses incurred by investors relying on the information provided in this document.